-
Harvard Bioscience gets 180-day extension to meet NASDAQ bid price rule
-
Harvard Bioscience expands Fisher Scientific deal to US market
-
Harvard Bioscience Inc. (HBIO) PT Lowered to $2 at Benchmark as Healthcare Faces 'Tough Year'
-
Benchmark Reiterates Speculative Buy Rating on Harvard Bioscience Inc. (HBIO)
-
Harvard Bioscience (HBIO) Appoints John Duke to Board of Directors
-
Harvard Bioscience (HBIO) Reports In-Line Q1 EPS
-
Benchmark Reiterates Speculative Buy Rating on Harvard Bioscience Inc. (HBIO)
-
Harvard Bioscience (HBIO) Announces CFO Transition
-
KeyBanc Downgrades Harvard Bioscience Inc. (HBIO) to Sector Weight
-
Harvard Bioscience Inc. (HBIO) PT Lowered to $4.50 at Benchmark
-
Harvard Bioscience (HBIO) Tops Q4 EPS by 1c
-
Harvard Bioscience (HBIO) Files for $100M Mixed Shelf
-
Harvard Bioscience (HBIO) Misses Q3 EPS by 4c
-
Harvard Bioscience Inc. (HBIO) PT Lowered to $5.50 at Benchmark
-
KeyBanc Reiterates Overweight Rating on Harvard Bioscience Inc. (HBIO)

